Patents by Inventor Patrick Rossignol

Patrick Rossignol has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SOLUBLE ST2 FOR THE IDENTIFICATION OF PROGRESSORS TO LVH IN THE GENERAL POPULATION
    Publication number: 20190279770
    Abstract: The present disclosure relates to a method of identifying a subject who is at risk of progressing to left ventricular hypertrophy (LVH), using the steps of measuring the amount of the biomarker soluble ST2 and comparing the thus measured amount to a reference. Further encompassed by the present disclosure are kits and devices adapted to carry out the method of the present invention.
    Type: Application
    Filed: October 12, 2018
    Publication date: September 12, 2019
    Applicants: Roche Diagnostics Operations, Inc., Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu
    Inventors: Dirk Block, Ursula-Henrike Wienhues-Thelen, Christian Zaugg, Andre Ziegler, Faiez Zannad, Patrick Rossignol
  • Methods for the treatment of cardiovascular fibrosis
    Patent number: 10167468
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of cardiovascular fibrosis. In particular, the present invention relates to an inhibitor of Neutrophil Gelatinase-Associated Lipocalin (NGAL) activity or expression for use in a method for treating or preventing cardiovascular fibrosis in a subject in need thereof.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: January 1, 2019
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITE DE LORRAINE, CENTRE HOSPITALIER ET UNIVERSITAIRE DE NANCY (CHU), UNIVERSITE PARIS DIDEROT-PARIS 7, UNIVERSITE PARIS DESCARTES
    Inventors: Frederic Jaisser, Nicolette Farman, Antoine Tarjus, Patrick Rossignol, Faiez Zannad
  • Methods and Pharmaceutical Compositions for the Treatment of Cardiovascular Fibrosis
    Publication number: 20170166892
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of cardiovascular fibrosis. In particular, the present invention relates to an inhibitor of Neutrophil Gelatinase-Associated Lipocalin (NGAL) activity or expression for use in a method for treating or preventing cardiovascular fibrosis in a subject in need thereof.
    Type: Application
    Filed: January 31, 2017
    Publication date: June 15, 2017
    Inventors: Frederic Jaisser, Nicolette Farman, Antoine Tarjus, Patrick Rossignol, Faiez Zannad
  • Method for the treatment of cardiovascular fibrosis
    Patent number: 9594083
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of cardiovascular fibrosis. In particular, the present invention relates to an inhibitor of Neutrophil Gelatinase-Associated Lipocalin (NGAL) activity or expression for use in a method for treating or preventing cardiovascular fibrosis in a subject in need thereof.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: March 14, 2017
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite de Lorraine, Cantre Hospitalier et Universitaire de Nancy (CHU), Universite Paris Diderot-Paris 7, Universite Paris Descartes
    Inventors: Frederic Jaisser, Nicolette Farman, Antoine Tarjus, Patrick Rossignol, Faiez Zannad
  • Methods and Pharmaceutical Compositions for the Treatment of Cardiovascular Fibrosis
    Publication number: 20150247855
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of cardiovascular fibrosis. In particular, the present invention relates to an inhibitor of Neutrophil Gelatinase-Associated Lipocalin (NGAL) activity or expression for use in a method for treating or preventing cardiovascular fibrosis in a subject in need thereof.
    Type: Application
    Filed: September 27, 2013
    Publication date: September 3, 2015
    Inventors: Frederic Jaisser, Nicolette Farman, Antoine Tarjus, Patrick Rossignol, Faiez Zannad
  • Methods and kits for detecting cardiac remodeling in subjects without clinical signs of heart failure
    Patent number: 9121858
    Abstract: The present relates to a method for detecting cardiac remodeling in a subject without clinical signs of heart failure comprising determining the level of the NGAL-MMP9 complex in a blood sample obtained from the patient.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: September 1, 2015
    Assignees: Institute National de la Sante et de la Recherche Medicale (INSERM), Universite de Lorraine, Centre Hospaitalier et de Nancy (CHU), Universite Paris Descartes
    Inventors: Frederic Jaisser, Patrick Rossignol, Faiez Zannad
  • METHODS FOR THE DETECTION AND THE TREATMENT OF DIASTOLIC DYSFUNCTION
    Publication number: 20150005260
    Abstract: The present invention relates to methods and kits for detecting diastolic dysfunction in subjects without clinical signs of heart failure.
    Type: Application
    Filed: January 2, 2013
    Publication date: January 1, 2015
    Inventors: Faiez Zannad, Patrick Rossignol
  • METHODS FOR THE DETECTION AND THE TREATMENT OF CARDIAC REMODELING
    Publication number: 20140248284
    Abstract: The present invention relates to methods and kits for detecting cardiac remodeling in subjects without clinical signs of heart failure. The present invention also relates to methods and pharmaceutical compositions for the prevention and the treatment of cardiac remodeling.
    Type: Application
    Filed: October 22, 2012
    Publication date: September 4, 2014
    Inventors: Faiez Zannad, Patrick Rossignol
  • METHODS AND KITS FOR DETECTING CARDIAC REMODELING IN SUBJECTS WITHOUT CLINICAL SIGNS OF HEART FAILURE
    Publication number: 20140249121
    Abstract: The present relates to a method for detecting cardiac remodeling in a subject without clinical signs of heart failure comprising determining the level of the NGAL-MMP9 complex in a blood sample obtained from the patient.
    Type: Application
    Filed: October 12, 2012
    Publication date: September 4, 2014
    Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Frederic Jaisser, Patrick Rossignol, Faiez Zannad
  • METHOD FOR DETERMINING A PLASMA VOLUME VARIATION AND DEVICES FOR IMPLEMENTING THE METHOD
    Publication number: 20140120572
    Abstract: Method for monitoring the evolution of heart failure in a patient comprising determining in vitro a physiological human parameter in a patient, comprising the steps consisting of: i) measuring values of two or more human parameters (P1, P2, . . . , PN) at time t1 wherein one or more of the human parameters (P1t1, P2t2, . . . PNt1) is obtained from a human physiological fluid sample, ii) measuring values of the same two or more parameters (P1t2, P2t2, . . . PNt2) at time t2 different from time t1, and iii) determining the physiological human parameter wherein the physiological human parameter is a plasma volume variation ?V between time t2 and time t1 from the values (P1t1, P2t1, PNt1, P1t2, P2t2, . . . PNt2) obtained at times t1 and t2, and devices for implementing said method.
    Type: Application
    Filed: June 15, 2012
    Publication date: May 1, 2014
    Applicants: UNIVERSITE DE LORRAINE, INSERM (Institut National de la Sante et de la Recherche Medicale), CENTRE HOSPITALIER UNIVERSITAIRE DE NANCY (CHU)
    Inventors: Faiez Zannad, Patrick Rossignol